Cognitive enhancement, memory support, focus, stress resilience — the language of nootropic marketing is rich and aspirational. It's also a minefield. Brain health claims that reference specific cognitive conditions (ADHD, Alzheimer's, depression, anxiety), even implicitly, convert a supplement into an unapproved drug under FDA regulations. And the nootropic category is full of brands using exactly that kind of language.

What FDA Permits for Brain and Cognitive Claims

Under 21 CFR 101.93(f), supplement labels may describe how ingredients affect the structure or function of normal brain and cognitive function. These claims are permitted:

• "Supports healthy cognitive function"

• "Promotes mental clarity and focus"

• "Helps maintain normal memory function"

• "Supports healthy brain function"

• "Promotes stress resilience"

• "Supports healthy neurotransmitter function"

• "Helps maintain normal concentration"

These work because they describe support for cognitive processes in healthy individuals — not the treatment of cognitive dysfunction, neurological disease, or psychiatric conditions.

Where Nootropic Claims Become Disease Claims

Under 21 CFR 101.93(g)(2)(ii), a claim that references the characteristic signs or symptoms of a disease — using scientific or lay terminology — is a disease claim. Cognitive decline, memory impairment, inability to concentrate, and mood disorders are all signs or symptoms of named medical conditions. Claims that reference these conditions, even indirectly, are disease claims.

These are prohibited disease claims:

• "Improves memory in people with cognitive decline" — references a disease state

• "Helps with ADHD symptoms" — ADHD is a named condition

• "Reduces anxiety" — anxiety disorders are classified diseases; this claim implies treatment

• "Fights depression" — explicit disease claim

• "Prevents Alzheimer's disease" — named disease prevention

• "Helps with brain fog from long COVID" — references a specific disease condition

• "Improves focus in people with attention problems" — implies treatment of attention disorders

• "Reduces symptoms of stress and burnout" — burnout has been classified as a medical condition by WHO since 2019

The anxiety and stress distinction

"Promotes stress resilience" and "supports a healthy stress response" are structure/function claims — they describe how the body manages normal stress. "Reduces anxiety" is a disease claim — anxiety disorders are classified mental health conditions. The distinction matters because the same ingredient (say, ashwagandha) might be used to substantiate both types of claims. The claim you're allowed to make isn't determined by the ingredient; it's determined by what you're claiming the ingredient does.

The Memory Claim Problem

"Supports healthy memory" is a permitted structure/function claim for healthy adults. "Improves memory in people experiencing cognitive decline" references a disease state and is prohibited. "Helps maintain normal memory as you age" exists in a gray zone — the FDA has not clearly established whether age-related memory changes constitute a "disease" in all circumstances, but has taken enforcement action in cases where the framing implies treatment of abnormal cognitive decline.

The safest framing for memory claims: describe support for normal memory function in healthy adults, without referencing age-related decline, cognitive impairment, or conditions like MCI (mild cognitive impairment).

Ingredient-Specific Considerations

Bacopa monnieri: Has clinical evidence for effects on memory and cognitive performance. Structure/function claims about supporting memory function may be substantiated at appropriate doses.

Lion's mane mushroom: Growing evidence base for neurotrophic effects. Claims about supporting brain health and cognitive function may be supportable; claims about treating neurodegenerative conditions are not.

Ashwagandha: Clinical evidence for stress-related outcomes. "Supports a healthy stress response" and "promotes stress resilience" are defensible. "Treats anxiety disorder" is not.

Phosphatidylserine: One of the few nootropic ingredients with an FDA qualified health claim — specifically, a claim about its potential role in reducing the risk of cognitive dysfunction in the elderly, with the disclaimer that the evidence is limited and not conclusive.

Racetams and synthetic nootropics: Many synthetic compounds marketed as nootropics (piracetam, aniracetam) have not been approved as food ingredients or dietary supplements by the FDA. Marketing products containing these compounds as dietary supplements may itself be a violation, regardless of the claims made.

New Dietary Ingredient Considerations

Many nootropic ingredients — particularly novel compounds and botanical extracts that weren't on the market before October 15, 1994 — require a New Dietary Ingredient (NDI) notification submitted to the FDA before marketing. This is a separate obligation from structure/function claim notification under 21 CFR 101.93(a), and it's frequently overlooked by brands launching in the nootropic space.

Marketing a supplement containing a new dietary ingredient without an accepted NDI notification is a violation independent of any claim on the label.

Nootropic marketing needs more regulatory discipline, not less

The nootropic category's consumer appeal is built on outcome language — "think better, focus sharper, remember more." That language, when it crosses the line FDA draws under 21 CFR 101.93(g), creates serious enforcement exposure. Truli scans nootropic and brain health claims against the structure/function framework and flags disease-adjacent language before it goes on a label, a product page, or into an influencer brief.

A note from Truli: Truli is not a law firm, and this article does not constitute or contain legal advice or create an attorney-client relationship. When determining your obligations and compliance with respect to relevant laws and regulations, you should consult a licensed attorney.